Abstract
De novo lymphangiogenesis influences different pathological courses via modulating tissue fluid homeostasis, macromolecule absorption, and leukocyte transmigration. During the past decade, improved understanding of lymphatic biology, especially VEGF-C/- D/VEGFR-3-mediating lymphangiogenesis has substantially promoted clinical research in lymphatic insufficiency. The role of lymphangiogenesis in the setting of the inflammatory processes observed in transplants, inflamed cornea, wound healing, acquired lymphedema and tumor invasion, however, remains to be elucidated. The chemokine family of peptide chemoattractants and other mediators, e.g., CCL21-CCR7, D6, NF-κB and TNF-α may be important contributors to pathophysiological changes of lymphatic endothelial cells (LECs) and inflammatory lymphangiogenesis. Dendritic cells and macrophages may also involve in LEC proliferation and differentiation. Increased knowledge of LEC-specific modulators in inflammatory microenvironment is vital for prevention and treatment of lymphatic- associated diseases.
Keywords: Lymphatic endothelial cells, lymphangiogenesis, inflammation, VEGF-C/-D/VEGFR-3, CCL21-CCR7, D6, NF-κB, TNF-α
Current Medicinal Chemistry
Title: Lymphatic Endothelial Cells, Inflammatory Lymphangiogenesis, and Prospective Players
Volume: 14 Issue: 22
Author(s): R. C. Ji
Affiliation:
Keywords: Lymphatic endothelial cells, lymphangiogenesis, inflammation, VEGF-C/-D/VEGFR-3, CCL21-CCR7, D6, NF-κB, TNF-α
Abstract: De novo lymphangiogenesis influences different pathological courses via modulating tissue fluid homeostasis, macromolecule absorption, and leukocyte transmigration. During the past decade, improved understanding of lymphatic biology, especially VEGF-C/- D/VEGFR-3-mediating lymphangiogenesis has substantially promoted clinical research in lymphatic insufficiency. The role of lymphangiogenesis in the setting of the inflammatory processes observed in transplants, inflamed cornea, wound healing, acquired lymphedema and tumor invasion, however, remains to be elucidated. The chemokine family of peptide chemoattractants and other mediators, e.g., CCL21-CCR7, D6, NF-κB and TNF-α may be important contributors to pathophysiological changes of lymphatic endothelial cells (LECs) and inflammatory lymphangiogenesis. Dendritic cells and macrophages may also involve in LEC proliferation and differentiation. Increased knowledge of LEC-specific modulators in inflammatory microenvironment is vital for prevention and treatment of lymphatic- associated diseases.
Export Options
About this article
Cite this article as:
Ji C. R., Lymphatic Endothelial Cells, Inflammatory Lymphangiogenesis, and Prospective Players, Current Medicinal Chemistry 2007; 14 (22) . https://dx.doi.org/10.2174/092986707781745541
DOI https://dx.doi.org/10.2174/092986707781745541 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prodrugs and Endogenous Transporters: Are They Suitable Tools for Drug Targeting into the Central Nervous System?
Current Pharmaceutical Design Alternative Splicing and Tumor Progression
Current Genomics New Strategies and Biological Agents in the Treatment of Autoimmune Inflammatory Diseases. Progress and Challenges
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Eph/Ephrin Signalling and Function in Oncogenesis: Lessons from Embryonic Development
Current Cancer Drug Targets Biologic Therapy in Psoriasis: Safety Profile
Current Drug Safety Current and Future Challenges in Primary Sjogren’s Syndrome
Current Pharmaceutical Biotechnology Naphthoflavones as Antiproliferative Agents: Design, Synthesis and Biological Evaluation
Anti-Cancer Agents in Medicinal Chemistry Impact of PET on the Radiation Treatment of Hodgkins Lymphoma
Current Radiopharmaceuticals Approaches for Developing Novel Microtubule Targeting Agents (MTAs) for Therapeutic Exploitation
Current Pharmaceutical Design Ocular Toxicities in Cancer Therapy: Still Overlooked
Current Cancer Therapy Reviews Editorial
Current Pharmaceutical Biotechnology Progenitor Cell Types in HIV-1 Infection: Bioactivity and Emerging Targets for Treatment
Current HIV Research Cervical Cancer: Are There Potential New Targets? An Update on Preclinical and Clinical Results
Current Drug Targets Emerging Role of GPR30/GPER1 in Skeletal Metabolism
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Polyphenols: Biological Activities, Molecular Targets, and the Effect of Methylation
Current Molecular Pharmacology COX-2 Selective Inhibitors, Carbonic Anhydrase Inhibition and Anticancer Properties of Sulfonamides Belonging to This Class of Pharmacological Agents
Mini-Reviews in Medicinal Chemistry Immune Modulation by Ionizing Radiation and its Implications for Cancer Immunotherapy
Current Pharmaceutical Design Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Neurodegenerative Diseases and Flavonoids: Special Reference to Kaempferol
CNS & Neurological Disorders - Drug Targets Therapeutic and Diagnostic Applications of Nanoparticles
Current Drug Targets